Introduction Patients presenting with chest pain do so at varying times following its onset. In addition, their histories can be unreliable, making the interpretation of time-dependent biochemical markers difficult. Patients are therefore subsequently managed according to measurements of specific markers, such as troponin, taken many hours following their admission. Earlier markers such as myoglobin and heart fatty acid binding protein (hFABP) may provide information earlier; however, the true role of such markers remains unclear when applied to real life patient cohorts. We aimed to evaluate and compare the diagnostic accuracy of the early markers hFABP and myoglobin (in terms of area under ROC curves, sensitivity and specificity) to troponin I (cTnI) in a pragmatic group of patients presenting with chest pain.
Introduction
Cardiac markers provide essential information for accurate, timely triaging, diagnosis of acute myocardial infarction (AMI) and early, non-invasive detection of reperfusion following thrombolytic treatment. 1^3 Cardiac troponin, increasingly used in patients presenting with undi¡erentiated chest pain or dyspnoea to aid the diagnosis of an acute coronary syndrome, 4 is now regarded as the gold standard for triaging patients admitted with chest pain, along with clinical judgment. 5^7 Indeed, the recent new criteria for the de¢nition of MI issued jointly by the American College of Cardiology and the European Society of Cardiology (ACC/ESC) relies heavily on the presence of a typical rise of a marker such as troponin. 8, 9 Despite this, there is no single marker available today that is capable of meeting all the criteria for an ideal marker; 10 a signi¢cant drawback of troponin is its insu⁄cient sensitivity in the early stages or hours of presentation with a MI, 11 necessitating the need for other approaches at this stage. A multi-marker approach has been suggested, using markers with early, short time windows 12, 13 in order to avoid the limitations associated with troponin use. Despite what appear to be promising reported negative predictive
Original Article values, such approaches are limited by a lack of speci-¢city. 14 Various studies have raised the possibility of the use of heart fatty acid binding protein (hFABP) as an early rule-out marker for MI example that by Seino et al., 15 which suggested that hFABP has the advantage of being more speci¢c than myoglobin. Others have established the idea of hFABP being more sensitive for AMI than other markers 16, 17 including troponin during the early hours of presentation; 18 however, agreement with this concept has not been universal. 19 Studies have also been published demonstrating the use of myoglobin as an AMI rule-out tool in carefully selected patient groups outside of the UK; however, studies looking at pragmatic groups of patients presenting with chest pain to NHS centres within the UK are limited. In this study we have aimed to evaluate and compare the diagnostic accuracy and clinical value of the early markers hFABP and myoglobin to troponin I (cTnI) in patients presenting with chest pain.
Methods

Patients and sample collection
A total of 302 patients consecutively admitted with chest pain to the coronary care triage unit at Aberdeen Royal In¢rmary, UK between 15 January 2002 and 30 June 2002, who met eligibility criteria (suspected cardiac chest pain) and were willing to provide informed consent themselves or by their relatives were included in the study. Study blood samples were collected in addition to routine samples from each patient at the time of admission and 12 h later. Blood samples were then sent to the clinical biochemistry department where they were centrifuged, separated, aliquoted and stored at 7848C until analysis.
Assay performance and sample analysis
Both cTnI and myoglobin were measured with highly speci¢c monoclonal antibodies in a sensitive chemiluminescence assay with the Bayer Advia Centaur analyser (Bayer Diagnostics, Tarrytown NY, USA). cTnI was measured on sample receipt, while myoglobin was measured in batches from stored plasma (within 6 months). The lowest measurable value of cTnI was 0.1 mg/L 20 and that of myoglobin was 3 mg/L (manufacturers data). The precision of the tests (coe⁄cient of variation) varied between 8.3% (mean 28.81 mg/L) and 19.5% (mean 0.48 mg/L) for cTnI and 2.4% (mean 148.1 mg/L) to 3.5% (mean 65.3 mg/L) for myoglobin. hFABP measurement was performed by a sandwichtype enzyme-linked immunosorbent assay (ELISA) on stored frozen plasma samples (hFABP ELISA method; HyCult Biotechnology, Uden, The Netherlands) in batches (within 6 months of receipt). The detailed speci¢cations of the hFABP assay have been described elsewhere. 21 The sensitivity of the assay was 0.1 mg/L, while coe⁄cients of variation varied between 0.4% (mean 1.5 mg/L) and 10% (mean 0.64 mg/L). Recoveries of between 87.8% (mean measured 468.6 mg/L) and 106.6% (mean measured 66 mg/L) were attained. Only results for cTnI were reported back to the clinician and therefore only they a¡ected clinical care.
Clinical classification
The diagnosis made by the attending clinician was obtained from the patient's case notes. Diagnosis of AMI was also made retrospectively according to the ACC/ESC new de¢nition of MI that includes a troponin rise 50.1 mg/L associated with one of the following symptoms (chest pain).
Ethical consideration
The study protocol was approved by the Grampian Research Ethics Committee, the University of Aberdeen and Grampian University Hospitals Trust. Written informed consent was obtained from each patient or a suitable relative as an alternative.
Statistical analysis
SPSS for Windows, standard version, release 10.0, 1989^1999 (SPSS Inc, Chicago IL, USA) and Analyse-it, general and clinical laboratory statistics 1997^2000, version 1.68 (Analyse-it Software Ltd, Leeds, UK) were used. Calculations of the median and inter-quartile ranges were used for non-parametric distributions. ROC curve analysis was used to evaluate the diagnostic ability of each test. A two-sided P50.05 was regarded as statistically signi¢cant.
Results
Baseline demographic and clinical factors
Six samples for myoglobin on admission and 10 samples for myoglobin and one sample for hFABP at 12 h were missing as a result of analytical error (see Fig. 1 ). Figure 1 also shows that in a further 12 patients the diagnosis of AMI by the clinician criteria was not clear. As a result the main analysis was carried out with these patients excluded. 
Cardiac markers
Diagnostic value of the biochemical markers
ROC curve analysis for the diagnosis of AMI (using new de¢nition MI and clinician criteria) was performed for the markers hFABP and myoglobin and compared to that of cTnI from the two time points. The area under each ROC curve (AUC) was calculated as a measure of overall diagnostic power. These results are displayed in Table 1 . The cTnI AUC was highest for the admission samples; however, this was only statistically signi¢cantly di¡erent from the AUC for hFABP (P50.001). At 12 h, the cTnI AUC was statistically greater than the AUC for both myoglobin (P50.001) and hFABP (P50.001).
Arguably the bene¢t of having an early marker is most useful when the admission troponin is negative, since in those patients with a positive troponin on admission the diagnosis is already made with a high degree of speci¢city. ROC curve analysis for the subsequent diagnosis of AMI by both criteria was therefore carried out for the admission myoglobin and hFABP concentrations only in those patients who were initially negative for cTnI (n ¼ 200). Six of these patients were excluded from the analysis owing to missing myoglobin results (see Fig. 1 ), and a further eight patients were excluded as a result of inconclusive diagnosis by the clinician criteria. These results, along with the relative performance of each marker when sensitivity was ¢xed at 100% and 90%, are shown in Table 2 .
Since both myoglobin and hFABP are promoted as early markers, their relative diagnostic power compared to troponin may be better if only those patients presenting early were considered. Consequently, the performances of the markers in those patients presenting within 4 h (n ¼100; mean ¼ 2.1h, 95% CI 1.9^2.3 h) of the onset of their chest pain was considered. Two of these patients were excluded from the analysis owing to missing myoglobin results (see Fig. 1 ) and a further three patients were excluded as a result of inconclusive diagnosis by the clinician criteria. These results demonstrated that even in this selective group, the diagnostic value of an admission troponin concentration (new de¢nition MI criteria ROC AUC 0.766, P50.001, 95% CI 0.665^0.867; clinician criteria AMI ROC AUC 0.669, P50.001, 95% CI 0.553^0.786) was at least as good as the performance of admission myoglobin (new de¢nition MI criteria ROC AUC 0.779, P 50.001, 95% CI 0.680^0.869; clinician criteria AMI ROC AUC 0.664, P50.001, 95% CI 0.539^0.785) or hFABP (new de¢nition MI criteria ROC AUC 0.608, P ¼ 0.03, 95%CI 0.497^0.721; clinician criteria AMI ROC AUC 0.560, P ¼ 0.2, 95% CI 0.426^0.666).
In patients who present with ST segment elevation on their ECG, the diagnosis of MI can easily be made. It is also likely that such patients would have positive cardiac markers. The performance of the admission markers was therefore assessed in the cohort of patients who did not have ST segment elevation on presentation (n ¼ 246). Five of these patients were excluded from the analysis owing to missing myoglobin results (see Fig. 1 ) and a further 12 patients were excluded as a result of inconclusive diagnosis by the clinician criteria. ROC curve analysis was performed, with the AUCs calculated according to both clinician (FABP ROC AUC 0.611; 95% CI 0.5170 .705, myoglobin ROC AUC 0.667; 95% CI 0.572^0.762, cTnI ROC AUC 0.699; 95% CI 0.601^0.796) and ACC/ ESC new de¢nition MI criteria (FABP ROC AUC 0.597; 95% CI 0.521^0.672, myoglobin ROC AUC 0.724; 95% CI 0.637^0.791, cTnI ROC AUC 0.777; 95% CI 0.7080 .846). There were no signi¢cant di¡erences in the ROC AUCs for troponin versus hFABP (P ¼ 0.04; P ¼ 0.05) or myoglobin (P ¼ 0.05; P ¼ 0.08) for the diagnosis of AMI by the clinician or by new de¢nition MI criteria, respectively.
Discussion
Biochemical markers of myocardial damage are of critical importance in the evaluation of patients presenting with chest pain. 21 Troponins, regarded as the diagnostic gold standard for the diagnosis of AMI, o¡er great diagnostic speci¢city with their ability to identify patients with minimal amounts of myocardial damage. Their sensitivity is, however, lacking in the early phases of presentation, and so it has been suggested that a strategy employing early (albeit low speci¢city) markers in combination with troponin testing may improve the overall diagnostic pick up at this stage and aid clinical decision making. 22^26 The utilities of two markers, myoglobin and hFABP, have previously been assessed 19, 27, 28 in a variety of patient cohorts and clinical settings. In this study the aim was to assess these markers in a pragmatic fashion using two conveniently timed blood samples taken with reference to the point of admission to hospital rather than to attempt to obtain samples with reference to the unreliable time point of the onset of chest pain. The criteria surrounding the diagnosis of AMI remains a controversial topic 29 despite the publication of the new diagnostic criteria by the ACC/ESC. 8 Indeed, in this study it is clear that the clinicians' diagnosis was largely underestimating those patients that would have been classi¢ed as having AMI by the new criteria.
Despite this study being based at a large city hospital with good transport facilities, the time of presentation in relation to the onset of chest pain appeared long at 5 h (median). Clearly this may have impacted on the performance of markers dependent on the early phase. Table 1 demonstrates the not-unexpected diagnostic superiority of cTnI over the other markers at 12 h from admission. This superiority is also evident for the admission sample, although to a lesser extent. Table 2 deals with only those patients who were initially negative for cTnI on admission. The overall performance of myoglobin and hFABP in this group is poor, especially when sensitivity is taken to the high concentration required for these markers to be used as rule-out tools. Indeed, even when only those patients presenting within 4 h from the onset of their chest pain are considered the overall diagnostic performance of myoglobin and hFABP do not improve over cTnI. A similar observation is seen when those patients who present with ST segment elevation are excluded.
Myoglobin is available as an automated test on many laboratory immunochemistry platforms; however, hFABP currently has no quantitative fast turnaround time assay. Its use as a marker for immediate clinical decision-making is therefore limited in this respect.
It is our view that when considering pragmatic cohorts of patients presenting with chest pain to UK hospitals, it is clear that they present at varying times in relation to the onset of chest pain and with potentially unreliable histories of such time points. Accordingly, cardiac marker decision-making is best made in relation to ¢xed known time points such as admission.
Our study supports the view that cTnI measurement taken at a time point distant to this (12 h in this study) provides the necessary sensitivity and speci¢city required for accurate clinical triaging. In addition, measurement of proposed early markers, such as myoglobin and hFABP, o¡er no advantage to admission troponin measurement and do not match the high degree of speci¢city that troponin positivity provides even at these early time points. Measurement of troponin on admission and a point in time distant to admission where speci¢city can be guaranteed provides the best and simplest diagnostic strategy for these patient cohorts.
